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Abstract  
 
Background: Asymmetric dimethylarginine (ADMA) is an endogenous nitric oxide 
synthase inhibitor and has been proposed to be an independent risk factor for 
cardiovascular diseases. However, little is known about its role in the regulation of 
lipid metabolism. In this study, we investigated the effect of ADMA on cholesterol 
metabolism and its underlying molecular mechanism.  
Methods: Oxidized low-density lipoprotein (oxLDL)-induced macrophage foam cells 
were used as an i  vitro model. Apolipoprotein E-deficient (apoE−/−) hyperlipidemic 
mice were used as an i vivo model. Western blot analysis was used to evaluate 
protein expression. Luciferase reporter assays were used to assess the activity of 
promoters and transcription factors. Conventional assay kits were used to measure the 
levels of ADMA, cholesterol, triglycerides, and cytokines. 
Results: Treatment with oxLDL decreased the protein expression of dimethylarginine 
dimethylaminohydrolase-2 (DDAH-2) but not DDAH-1. Incubation with ADMA 
markedly increased oxLDL-induced lipid accumulation in macrophages. ADMA 
impaired cholesterol efflux following oxLDL challenge and downregulated the 
expression of ATP-binding cassette transporter A1 (BCA1) and ABCG1 by 
interfering with liver X receptor α (LXRα) expression and activity. Additionally, this 
inhibitory effect of ADMA on cholesterol metabolism was mediated through the 
activation of the NADPH oxidase/reactive oxygen species pathway. In vivo 
experiments revealed that chronic administration of ADMA for 4 weeks exacerbated 
systemic inflammation, decreased the aortic protein l vels of ABCA1 and ABCG1, 
and impaired the capacity of reverse cholesterol transport, ultimately, leading to the 
progression of atherosclerosis in apoE−/− mice.  
Conclusion: Our findings suggest that the ADMA/DDAH-2 axis plays a crucial role 
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in regulating cholesterol metabolism in macrophage foam cells and atherosclerotic 
progression. 
 
Keywords: asymmetric dimethylarginine; macrophage foam cell; cholesterol 
metabolism; ATP-binding cassette transporter; liver X receptor α; atherosclerosis 
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Abbreviations: 
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cholesterol transport; NAC, N-acetylcysteine; APO, apocynin; DHE, dihydroethidine; 
DCFH-DA, 2′,7′-dichlorofluorescin diacetate; LXRE, LXRα responsive element; Adv, 
adenovirus; MOI, multiplicity of infection  
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1. Introduction 
Asymmetric dimethylarginine (ADMA) is generated from the degradation of 
methylated proteins and can be metabolized to citrulline by dimethylarginine 
dimethylaminohydrolase-1 (DDAH-1) or DDAH-2 [1]. DDAH-1 is abundant in the 
kidney and liver, whereas DDAH-2 expression can be detected in endothelial cells 
(ECs) and immune cells [1,2]. ADMA is now characteriz d as a circulating 
endogenous inhibitor of endothelial nitric oxide synthase (eNOS) [1,3]. Elevated 
plasma ADMA levels have been observed in patients wi h various risk factors for 
coronary artery disease (CAD), including hypercholesterolemia, atherosclerosis, 
hypertension, diabetes, insulin resistance, hypertriglyceridemia, and 
hyperhomocysteinemia [4-10]. Moreover, several studies have demonstrated that the 
plasma ADMA level may predict cardiovascular events and mortality in patients with 
CAD, renal failure, and advanced peripheral artery diseases [11,12]. During the past 
decades, most studies on the DDAH/ADMA system have in stigated its role in the 
regulation of eNOS activity in ECs. However, there has been little research on the role 
of ADMA in the pathophysiology of macrophages. 
It is well established that deregulation of cholesterol metabolism is the most 
critical factor for the initiation and development of atherosclerosis [13]. Excessive 
cholesterol deposition and persistent inflammation within the artery wall are two key 
hallmarks of atherosclerosis [13,14]. Both macrophage-mediated cholesterol clearance 
and pro-inflammatory cytokine secretion are crucial steps in the initiation and 
progression of atherosclerosis [13,15]. Particularly, excessive cholesterol 
accumulation in macrophages is mainly due to their uncontrolled uptake of oxidized 
low-density lipoprotein (oxLDL) or impaired cholestrol efflux [16-19]. Scavenger 
receptors (SRs) are responsible for internalizing oxLDL [17,18]. In contrast, the 
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efflux of intracellular cholesterol to apolipoprotein AI (apoAI) or high-density 
lipoprotein (HDL) is mediated through reverse cholesterol transport (RCT) [16,19]. 
Thus, moderating the expression of SRs and factors involved in RCT represents a 
possible therapeutic strategy for treating or preventing atherosclerosis [17,20-23]. 
However, less is known about the interlocking biology of ADMA and macrophages. 
Further investigations to delineate the role and molecular mechanisms of ADMA in 
the cholesterol metabolism of macrophage foam cellsare warranted. 
In this study, first, we investigated the role of ADMA in oxLDL-induced foam 
cell formation, and second, we determined whether ADM  affects the expression of 
SRs and factors involved in RCT and the underlying molecular mechanisms. Our 
third aim was to explore the effect of ADMA on the d velopment of atherosclerosis in 
apolipoprotein E-deficient (apoE-/-) mice. Here, we found that treatment with ADMA 
worsened the oxLDL-induced lipid accumulation of macrophage foam cells by 
decreasing ABC transporter-dependent cholesterol efflux. This detrimental effect of 
ADMA was attributed to a decrease in oxLDL-elicited LXRα activation. The in vivo 
response to ADMA may involve it modulating hyperlipidemia and systemic 
inflammation, as well as RCT, thus accelerating atherosclerosis progression. Our 
findings provide a novel explanation for the pro-atherogenic action of ADMA and 
suggest a potential molecular target for the treatmn  or prevention of atherosclerosis 
in the future. 
 
2. Materials and methods 
2.1. Reagents 
 
Goat anti-SR-A antibody (Ab), rabbit anti-CD36, anti-ABCG1, anti-DDAH-1, 
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anti-DDAH-2 Ab, control small interfering RNA (siRNA) and NADPH oxidase 2 
(NOX2) siRNA were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, 
USA). Mouse anti-ABCA1 Ab and rabbit anti-SR-BI Ab were purchased from Abcam 
(Cambridge, MA, USA). ADMA, Tri reagent, mouse anti-α-tubulin Ab, human apoAI, 
human HDL, human LDL, N-acetylcysteine (NAC), and apocynin (APO) were 
purchased from Sigma Chemical (St. Louis, MO, USA). The ADMA ELISA kit was 
obtained from Enzo Life Sciences (Farmingdale, NY, USA). Dil-labeled LDL or 
oxLDL was purchased from Biomedical Technologies (Stoughton, MA, USA). The 
cholesterol and triglyceride assay kits were obtained from Randox (Antrim, UK). 
3-hexanoyl-NBD-cholesterol was purchased from Cayman Chemical (Ann Arbor, MI, 
USA). TurboFectTM reagent was obtained from Fermentas (Glen Burnie, MD, USA). 
Dihydroethidine (DHE) and 2′,7′-dichlorofluorescin diacetate (DCFH-DA) were 
purchased from Molecular Probes (Eugene OR, USA). The EnzyChrom 
NADP+/NAD(P)H assay kit was obtained from BioAssay Systems (Hayward, CA, 
USA). ELISA kits for pro-inflammatory cytokines were purchased from R&D 
(Minneapolis, MN, USA).  
2.2. Cell culture 
Murine J774.A1 macrophages (ATCC, TIB-67) were cultured in RPMI 1640 
medium supplemented with 10% fetal bovine serum (FBS), penicillin (100 U/ml), and 
streptomycin (100 µg/ml). Human monocytic cell line THP-1 cells (Bioresource 
Collection and Research Center; Hsinchu, Taiwan) were cultured in RPMI 1640 
medium supplemented with 10% FBS, penicillin (100 U/ml) and streptomycin (100 
µg/ml). THP-1 cells were induced with 50 nM PMA for 5 d to differentiate into 
macrophages. 
2.3. Modification of low-density lipoprotein 
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oxLDL was prepared as described previously [22]. LDL was exposed to 5 µM 
CuSO4 for 24 h at 37 °C, and Cu2+ was then removed by extensive dialysis. The 
extent of modification was determined by measuring thiobarbituric acid-reactive 
substances (TBARs). OxLDL containing approximately 30-60 nmol TBARs defined 
as malondialdehyde equivalent per milligram LDL protein was used for experiments. 
HOCL-oxLDL was prepared by adding 1 mmol/L (Final con entration) NaOCl into 
LDL or Dil-LDL solutions (1 mg/mL) at 37◦C for 40 min, and HOCl was then 
removed by extensive dialysis.  
2.4. Oil red O staining 
Cells were fixed with 4% paraformaldehyde and then stained with 0.5% Oil red 
O. Hematoxylin was used for counterstaining.  
2.5. Quantitative real-time PCR (qRT-PCR) 
Total RNA was isolated from cells using Tri reagent a d then converted into 
cDNA by reverse transcriptase (Fermentas Glen Burnie, MD, USA) with oligo-dT 
primers. The obtained cDNAs were then used as the templates for qRT-PCR. The 
qRT-PCR reaction was performed using the TaqMan® probe-based real-time 
quantification system (Foster, CA). The relative amount of mRNAs was calculated 
with glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA as the invariant 
control. 
2.6. Preparation of nuclear extracts 
Nuclear extracts were prepared as described previously [22]. Cells were lysed in 
10 mM HEPES (pH 7.9), 10 mM KCl, 1.5 mM MgCl2, 0.5% Nonidet P-40, 1 µg/ml 
leupeptin, 10 µg/ml aprotinin, and 1 mM phenylmethylsulfonyl fluoride. Nuclei were 
pelleted at 5000 × g for 5 min at 4 °C, and the resulting supernatants were used as the 
cytosolic fraction. Nuclei were resuspended in 50 mM Tris (pH 7.5), 300 mM NaCl, 
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1% Triton X-100, 5 mM ethylenediaminetetraacetate, 1 µg/ml leupeptin, 10 µg/ml 
aprotinin, and 1 mM phenylmethylsulfonyl fluoride and incubated on ice for 5 min. 
After centrifugation at 12,000 × g for 5 min at 4 °C, the supernatant was collected as 
the nuclear extract. 
2.7. Western blot analysis  
Cells or tissues were lysed with PBS containing 1% Triton X-100, 0.1% SDS, 
0.5% sodium deoxycholate, 1 µg/ml leupeptin, 10 µg/ml aprotinin, and 1 mM PMSF 
on ice. After sonication, crude extracts underwent centrifugation at 12000 × g for 5 
min at 4 °C. The supernatants were collected as cell lysates. All protein concentrations 
were determined by a protein assay. Aliquots (50 µg) of cell lysates were separated 
using 8% SDS-PAGE and then transblotted on an ImmobilonTM-P membrane 
(Millipore, Bedford, MA). After blocking with 5% skim milk, blots were incubated 
with primary Abs and then secondary Abs. The protein bands were detected with an 
enhanced chemiluminescence kit (PerkinElmer, Boston, MA) and quantified using 
ImageQuant 5.2 software (Healthcare Bio-Sciences, PA). 
2.8. Cholesterol and triglyceride measurements 
Cellular cholesterol and triglycerides were extracted using hexane/isopropanol 
(3/2, v/v). The extracts were dried, and the reagent from the assay kit was then added 
to measure the levels of cholesterol and triglycerides. 
2.9. Dil-oxLDL binding assay 
The assay was performed as described previously [22]. Macrophages were 
treated with various concentration of ADMA (0, 0.25, 0.5, 1.0 µg/ml) for 12 h and 
then with 10 µg/ml Dil-oxLDL at 4 °C for 4 h. Cells were washed, and lysates were 
analyzed using fluorometry (Molecular Devices) with a 514-nm excitation laser line 
and 550-nm emission filters.  
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2.10. Cholesterol efflux assay 
The assay was performed as described previously [22]. Macrophages were 
treated with various concentrations of ADMA (0, 0.25, 0.5, 1.0 µg/ml) for 12 h and 
then equilibrated with NBD-cholesterol (1 µg/ml) for an additional 6 h in the presence 
of apoAI (10 µg/ml) or HDL (50 µg/ml) with or without ADMA. 
NBD-cholesterol-labeled cells were washed with PBS and incubated in RPMI 1640 
medium for 6 h. The fluorescence-labeled cholesterol r leased from the cells into the 
medium was measured using a multilabel counter (PerkinElmer, Waltham, MA). In 
vivo cholesterol efflux was determined as described previously with modifications 
[24]. Briefly, after removing the apoB-containing lipoproteins from mouse plasma, 
the supernatant, as the high-density lipoprotein fraction, was diluted to 2.8% 
(equivalent to 2% serum) in culture medium. Cholesterol efflux was measured as the 
difference in the release of fluorescence-labeled cholesterol from vehicle- or 
TO901317-treated macrophages. 
2. 11. Transient transfection and luciferase reporter assay 
Cells were transfected with the plasmids phABCA1 (-928)-Luc, a reporter plasmid for 
the human ABCA1 promoter, phABCA1-DR4m-Luc, a reporter plasmid with a 
mutation in the LXRα responsive element (LXRE) (kindly provided by Dr. A.R. Tall, 
Division of Molecular Medicine, Department of Medicine, Columbia University, New 
York, NY, USA) or in LXR/RXR ligand binding systems, pM-hLXRα or pM-hRXRα, 
respectively, and with pG5SEAP using TurboFectTM. The ligand binding domains of 
hLXRα and hRXRα were isolated from pENTR221-NR1H3 and pENTR221-NR1H2, 
respectively (Addgene, Watertown, MA, USA) and subcloned into the pM vector 
(Clontech, Mountain View, CA) using MluI and XbaI. The pGL3-renilla plasmid was 
cotransfected as a transfection control. After transfection for 24 h, cells were treated 
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with TO-901317 for another 18 h. The cells were then lysed for luciferase (Luc) and 
renilla activity assays. For siRNA transfection, macrophages were transfected with 
control siRNA or NOX2 siRNA with use of Lipofectamine for 24 h for the indicated 
experiments. 
2.12. Measurement of intracellular ROS levels 
Macrophages were washed with PBS and incubated in cell medium containing 
10 µM HE or 20 µM DCFH-DA at 37 °C for 30 min. Subsequently, the cell medium 
containing DHE or DCFH-DA was removed and replaced with fresh medium. Cells 
were then incubated with ADMA (0.5 µg/ml) for 0-30 min. Cells were washed twice 
with PBS and detached with trypsin/EDTA, and fluorescence intensity was analyzed 
using FACScan flow cytometry (Becton Dickinson, San Jose, CA, USA) at 530 nm 
excitation and 620 nm emission for ethidium (ETH) and 488 nm excitation and 530 
nm emission for DCF.  
2.13. Determination of NADPH oxidase activity 
Macrophages were incubated with ADMA (0.5 µg/ml) for different times or in 
the absence or the presence of NAC (10 mM) or APO (50 µM) for 15 min. The 
activity of NOX was analyzed using the EnzyChrom NADP+/NADPH assay kit.  
2.14. Adenoviral construction and infection 
A replication-defective recombinant adenoviral vector containing a human 
phosphoglycerate kinase (hPGK) promoter driving the uman DDAH-2 
(Adv-DDAH-2), as well as hPGK alone to serve as a control (Adv-null), were 
generated by homologous recombination according to the protocol provided 
(Clontech, Palo Alto, CA) and amplified in HEK293 cells, purified by CsCl 
ultracentrifugation, and stored in 10 mm Tris-HCl (pH 7.4), 1 mm MgCl2, and 10% 
(vol/vol) glycerol in liquid nitrogen until used for experiments. The titers of 
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adenovirus were determined by plaque assay in HEK293 cells. Macrophages were 
infected with Ad at multiplicity of infection (MOI) of 12.5-50 for 24 h and then 
subjected to experiments. 
2.15. Animals 
All animal experiments were approved by the Animal Care and Utilization 
Committee of National Yang-Ming University (No. 990803). Male apoE-/- mice 
(Jackson Laboratory, Bar Harbor, Maine) (4 months old) were fed a chow diet, which 
contained 4.5% fat by weight (0.02% cholesterol) (Newco Distributors, Redwood, CA) 
and maintained under conventional housing conditions. Mice received a daily 
intraperitoneal (i.p.) injection of ADMA (5 mg/kg, n=10) or saline (vehicle control, 
n=10) for 4 weeks. At the end of the experiments, mice were euthanized with CO2. 
Serum, hearts, and aortas were collected for blood bi chemistry, histology, and 
western blot analyses. 
2.16. Histological assessment 
Harvested hearts were fixed and embedded in paraffin. Heart tissue blocks were 
serially sectioned at 8 µm. For the quantification of atherosclerotic lesions, 50 serial 
sections from the aortic sinus of each mouse were coll cted. A total of 10 sections 
sampled from every 5 consecutive sections were deparaffinized and subjected to H&E 
staining. The photomicrographs of lesions at aortic root were taken under a Motic 
TYPE 102M microscope (Motic Images Plus 2.0, China). The lesion size was then 
calculated from the average of the area quantified from the 10 sections by use of a 
computer imaging software (Motic Images Plus 2.0, China).  
2.17. Serum lipid profile analysis 
Serum was collected from experimental mice. The serum levels of total 
cholesterol and triglycerides were measured using Spotchem EZ SP 4430 (ARKRAY, 
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Inc., Kyoto, Japan). 
2.18. Measurement of inflammatory cytokines 
The concentrations of pro-inflammatory cytokines, including tumor necrosis 
factor (TNF)-α, interleukin (IL)-1β, IL-6, monocyte chemoattractant protein-1 
(MCP-1), and macrophage inflammatory protein-2 (MIP-2) in serum were measured 
using ELISA kits according to the manufacturer’s intructions. 
2.19. Statistical analysis 
Results are presented as the mean ± standard error of the mean (SEM) from 5 
independent experiments or 10 mice. The Mann-Whitney est was used to compare 
two independent groups. The Kruskal-Wallis test followed by the Bonferroni post hoc 
analyses was performed to test multiple groups. SPSS v8.0 (SPSS Inc, Chicago, IL) 
was used for analyses. A difference was considered statistically significant when p 
<0.05. 
 
3. Results 
3.1. DDAH-2 is involved in the formation of macrophage foam cells 
We first investigated the distribution of DDAHs in aortas from hyperlipidemic 
apoE-/- mice. The expression of DDAH-1 and DDAH-2 was mainly confined to 
macrophage foam cells of atherosclerotic lesions (Fig. 1A). Modified LDL, in 
particular oxLDL, deregulates the cholesterol metabolism of macrophages, leading to 
the formation of foam cells and progression of atherosclerosis [13,15]. We thus 
determined whether oxLDL affects the expression of DDAH-2 in macrophages. We 
found that incubation with oxLDL dose-dependently decreased the protein expression 
of DDAH-2 but not DDAH-1 in macrophages (Fig. 1B). In addition, oxLDL increased 
the intracellular level of ADMA (Fig. 1C). Similar results were observed in human 
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THP-1-derived macrophages (Fig. 1D and E). Furthermore, treatment with ADMA 
increased oxLDL-induced lipid accumulation in macrophages (Fig. 2A-D). Similar to 
the results that found in murine macrophages, ADMA also exacerbated the 
oxLDL-induced lipid accumulation in human THP-1-deriv d macrophages (Fig. 2E 
and F). Moreover, ADMA aggravated HOCl-oxLDL-induced lipid accumulation in 
murine macrophages (Supplementary Fig. S1). These findings suggest that the 
DDAH-2/ADMA system may play a role in the regulation f lipid metabolism during 
the transformation of macrophage foam cells. 
3.2. ADMA interferes with oxLDL-induced ABC transporter-dependent cholesterol 
efflux in macrophages  
We delineated the mechanisms underlying the detrimental effect of ADMA on 
the formation of foam cells by determining the effect of ADMA on the regulation of 
cholesterol homeostasis and the expression of SRs and RCTs in murine J774.A1 
macrophages or human THP-1 derived macrophages. Treatment with ADMA did not 
affect Dil-oxLDL binding and the protein expression of scavenger receptors, 
including SR-A and CD36 (Fig. 3A-F). In contrast, treatment with ADMA 
significantly decreased the apoAI- or HDL-dependent cholesterol efflux in 
macrophages (Fig. 4A, B, D and E). Additionally, treating macrophages with ADMA 
decreased the oxLDL-induced increase in protein levels of ABCA1 and ABCG1 
without affecting the protein expression of SR-BI (Fig. 4C and F). These results 
suggest that ADMA exacerbates oxLDL-induced lipid accumulation in foam cells by 
interfering with ABC transporter-dependent cholesterol fflux.  
3.3. ADMA impairs oxLDL-mediated LXRα activation  
Furthermore, treatment with ADMA decreased the oxLDL-induced mRNA 
expression of ABCA1 and ABCG1, as revealed by RT-PCR (Fig. 5A), suggesting that 
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ADMA may modulate the expression of ABCA1 and ABCG1 through transcriptional 
regulation. To determine whether the key transcription factor LXRα is involved in 
ADMA-mediated downregulation of ABCA1 and ABCG1, we examined the effect of 
ADMA on the expression and activity of LXRα in macrophages. As shown in Fig. 5B, 
ADMA decreased the nuclear levels of LXRα elicited by oxLDL. Additionally, we 
found that treatment with ADMA decreased LXRα activity induced by oxLDL (Fig. 
5C). Similarly, treatment with ADMA also reduced the LXRα activity induced by the 
LXRα agonist TO901317 (Fig. 5C). These results indicate that the deregulation of 
LXRα activation is a crucial event in the ADMA-mediated xacerbation of lipid 
accumulation in foam cells.  
3.4. Overexpression of DDAH-2 abolishes the ADMA-induced impairment of 
cholesterol efflux and exacerbation of lipid accumulation in macrophages 
DDAH-2 plays a crucial role in regulating ADMA metabolism in macrophages 
[25]. We determined whether overexpression of DDAH-2 protects against the 
unfavorable effects of ADMA on cholesterol metabolism. Infection with Ad-DDAH-2 
dose-dependently increased DDAH-2 expression (Fig. 6A) and rescued 
ADMA-impaired apoAI- and HDL-dependent cholesterol efflux (Fig. 6B and C). 
However, Adv-null had no such an effect (data not shown) on cholesterol efflux by 
ADMA. In addition, overexpression of DDAH-2 decreasd the ADMA-induced 
increase in lipid accumulation following incubation with Dil-oxLDL (Fig. 6D and E). 
These results suggest that DDAH plays a protective role in the deregulation of lipid 
metabolism in macrophage foam cells. 
3.5. ADMA impairs cholesterol efflux by activating the NOX-ROS signaling 
pathway 
We then determined the molecular mechanism by which ADMA interferes with 
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cholesterol efflux in macrophages. The NOX-ROS signaling pathway has been 
reported to be involved in the detrimental effects of ADMA [26]. Our results 
demonstrated that ADMA (0.5 µg/ml) increased NOX activity as early as 2 min, with 
a peak level at 15 min (Fig. 7A). In addition, ROS production was increased with 
ADMA treatment as early as 5 min, with a peak level at 15 min (Fig. 7B-E). 
Pretreatment with the NOX inhibitor APO or antioxidant NAC abrogated the 
ADMA-induced increase in ROS production (Fig. 8A and B). To provide further 
evidence that the ROS-NOX signaling pathway is crucial in the ADMA-induced 
decrease in cholesterol efflux and increase in lipid accumulation, we depleted NOX 
activity or ROS production by treatment with APO or NAC, respectively. Our results 
showed that the detrimental effects of ADMA on cholesterol efflux and lipid 
accumulation were blunted with APO or NAC (Fig. 8C-F). Moreover, transfection 
with NOX2 siRNA prevented the detrimental effects of ADMA on ROS production 
(Fig. 8G and H) and oxLDL-mediated lipid accumulation (Fig. 8I and J). Thus, the 
ROS-NOX signaling pathway plays a crucial role in regulating the ADMA-mediated 
impairment of cholesterol metabolism in macrophages. 
3.6. ADMA administration impairs the capacity for RCT, aggravates systemic 
inflammation, and accelerates the progression of atherosclerosis in apoE-/- mice 
To confirm the in vitro findings, we used hyperlipidemic apoE-/- mice as an in 
vivo model to delineate the potential functional significance of ADMA in cholesterol 
metabolism, systemic inflammation, and atherosclerosis. Chronic administration of 
ADMA for 4 weeks increased the serum levels of ADMA (ADMA-treated group vs. 
vehicle-treated group = 2.17 ± 0.40 µmol/L vs. 1.11 ± 0.26 µmol/L) but did not alter 
the body weight (ADMA-treated group vs. vehicle-treated group = 28.2 ± 2.1 g vs. 
27.8 ± 1.6 g).  Histological examinations revealed that the size of atherosclerotic 
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lesions that developed in ADMA-treated apoE-/- mice was significantly greater than 
those found in vehicle-treated apoE-/- mice (Fig. 9A). Serum levels of total cholesterol, 
non-HDL-c, HDL-c and triglycerides were significantly increased in ADMA-treated 
apoE-/- mice (Fig. 9B). Furthermore, ADMA decreased the protein levels of LXRα, 
ABCA1, and ABCG1 in the aortas of apoE-/- mice without affecting the protein levels 
of SR-A, CD36, and SR-BI (Fig. 9C). The capacity for serum cholesterol reverse 
transport was significantly lower in ADMA-treated apoE-/- than in vehicle-treated 
apoE-/- mice (Fig. 9D). Moreover, treatment with ADMA exacerbated systemic 
inflammation as evidenced by elevated serum levels of TNF-α, IL-1β, IL-6, MCP-1, 
and MIP-2 (Fig. 9E). Collectively, these findings suggest that ADMA might be an 
important factor in the deregulation of cholesterol metabolism and systemic 
inflammation, as well as the progression of atherosclerosis in vivo (Fig. 10). 
 
4. Discussion 
In this study, we found that ADMA has a detrimental effect on cholesterol 
homeostasis during the transformation of macrophage foam cells. We first confirmed 
that the expression of DDAH-1 and DDAH-2 was mainly localized in macrophage 
foam cells. Furthermore, we demonstrated that oxLDL, the most critical atherog nic 
factor, downregulated the expression of DDAH-2 and consequently increased the 
intracellular level of ADMA. We also found that ADMA augmented oxLDL-induced 
lipid accumulation in macrophages. In addition, trea ment with ADMA impaired 
cholesterol efflux, as well as the expression of LXRα, ABCA1, and ABCG1 
following oxLDL treatment. Moreover, ADMA markedly increased NOX activity and 
ROS production. These detrimental effects of ADMA on ABC transporter-dependent 
cholesterol efflux and lipid accumulation were blunted by treatment with the ROS 
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scavenger NAC or NOX inhibitor APO or overexpression of DDAH-2. Finally, in 
vivo, administration of ADMA worsened aortic inflammation and deregulation of 
cholesterol metabolism and ultimately resulted in the progression of atherosclerosis in 
apoE-/- mice. This inhibitory effect of ADMA on cellular function is consistent with 
our previous report in which we found that ADMA abolishes the effects of the 
lipid-lowering drug simvastatin on phosphorylation of endothelial nitric oxide 
synthase (eNOS), NO production, and angiogenesis as well as the clinical benefits of 
statins [26]. Thus, our findings suggest that ADMA interferes with the lipid 
metabolism of macrophage foam cells by deregulating cholesterol clearance. 
Collectively, we provide the new evidence to support the pro-atherogenic role of 
ADMA in the transformation of foam cells and the development of atherosclerosis. 
Regarding to the relevance of the levels of ADMA adde  in vitro studies, we 
believe that the concentration of exogenous ADMA (0.5 µmol/L) used in this study is 
clinically relevant. Our previous study demonstrated hat the circulating level of 
ADMA in CAD patients was about ~0.5 µmol/L [26]. Moreover, a meta-analysis 
study demonstrated the plasma levels of ADMA in CAD patients were range from 
0.345±0.178 to 3.43±0.57 µmol/L [27], suggesting the serum levels of ADMA in 
apoE-/- mice with or without ADMA administration of daily i.p. injection at 5 mg/kg 
(ADMA-treated group vs. vehicle-treated group = 2.17 ± 0.40 µmol/L vs. 1.11 ± 0.26 
µmol/L) were related that in CAD patients.  
The accumulation of macrophage foam cells in the intima of the aorta is a key 
event in the initiation and progression of atherosclerosis [28]. RCT is a crucial 
regulatory mechanism for cholesterol clearance from the human body [29]. ABCA1 
and ABCG1 are the key players in this process [30,31]. Increased expression of 
ABCA1 or ABCG1 in macrophages promotes cholesterol efflux and decreases 
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cholesterol accumulation in foam cells, thereby slowing the progression of 
atherosclerosis [23,31-33]. In contrast, loss of ABCA1 or ABCG1 function impairs 
RCT and results in cholesterol accumulation in foam cells, leading to the acceleration 
of atherosclerosis [34,35]. Our current findings further confirmed this notion by 
providing evidence that ADMA decreased the expression of ABCA1 and ABCG1 and 
impaired RCT, leading to an increase in intracellular cholesterol accumulation in 
macrophages following oxLDL challenge. In view of their function, the 
downregulation of both ABCA1 and ABCG1 by ADMA observ d in this study is 
likely to decrease cholesterol metabolism and promote f am cell formation. Notably, 
intralesional macrophage-mediated pro-inflammatory mediator secretion also plays a 
crucial role in the progression of atherosclerosis [36,37]. Deregulation of the 
DDAH-ADMA system has been reported to be involved in the pathogenesis of sepsis 
and metabolic diseases [38-40]. Several lines of evidence indicate that treatment with 
ADMA upregulates the expression of pro-inflammatory mediators, including IL-8, 
inducible NOS, and macrophage migration inhibitory factor in macrophages [41,42]. 
Indeed, our in vivo results further confirmed this, as chronic treatment with ADMA 
for 4 weeks increased the levels of TNF-α, IL-1β, IL-6, MCP-1, and MIP-2 in the 
sera of apoE-/- mice.  
NOX-derived ROS is an essential secondary messenger for regulating cellular 
functions and the progression of cardiovascular diseases [43]. In the initial stage of 
cardiovascular diseases, NOX-ROS signaling-elicited oxidative stress deregulates 
intracellular signaling cascades and cellular functions and leads to disease progression 
[44,45]. Targeting NOX-ROS signaling with antioxidants has been shown to be a 
successful and potential therapeutic strategy for preventing oxidative stress-induced 
pro-atherogenic events in clinical trials and experim ntal studies [21,46,47]. Growing 
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lines of evidence suggest that the NOX-ROS signaling pathway contributes to the 
ADMA-mediated pathological effects [41,48,49], so activation of this pathway might 
be required for the detrimental effects of ADMA on cholesterol metabolism in 
macrophage foam cells. Indeed, our findings that treatment with NAC or APO 
abrogated the ADMA-mediated deregulation of cholesterol metabolism in 
macrophages agree with our previous findings that ADM  abolished the beneficial 
effects of simvastatin by triggering NOX-ROS signali g [26].  
In addition to it inhibiting the ADMA-mediated activation of NOX-ROS 
signaling, we found that increasing the metabolic rate of ADMA by overexpressing 
DDAH-2 abrogated the ADMA-elicited activation of NOX-ROS signaling and thus 
prevented its detrimental effects on cholesterol metabolism in macrophage foam cells, 
which agrees with the findings reported by Jacobi et al. who found that 
overexpression of DDAH-1 lowers ADMA levels and ameliorates atherosclerosis in 
apoE-/- mice [50]. Moreover, we previously reported that the endothelium-specific 
overexpression of DDAH-2 prevents ADMA-induced interference with 
statin-mediated NO production and related endothelial functions [26]. Conceivably, 
these findings suggest that targeting ADMA represents a possible strategy for 
preventing the deregulation of cholesterol metabolism and the progression of 
atherosclerosis. Nevertheless, determining whether antioxidant therapy can prevent 
the ADMA-mediated detrimental effects on cholesterol metabolism and 
atherosclerosis requires further investigations and cli ical trials. 
We also showed that ADMA downregulated the expression of LXRα, the major 
transcriptional factor for the expression of ABCA1 and ABCG1, in ADMA-treated 
macrophages and apoE-/- mice [51,52]. LXRα is a cholesterol-sensing nuclear 
receptor and plays a crucial role in regulating cholesterol homeostasis in macrophages 
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and the pathogenesis of atherosclerosis [53]. It has been reported that activation of 
LXRα ameliorates lipid accumulation in macrophage foam cells and slows the 
progression of atherosclerosis [54,55]. Thus, our finding that ADMA downregulated 
LXRα, ABCA1, and ABCG1; impaired cholesterol efflux; and promoted the 
progression of atherosclerosis is not surprising. Apart from the anti-atherogenic effect 
on lipid metabolism, LXRα was recently found to play roles in the regulation of the 
inflammatory response [56,57]. As such, the anti-inflammatory property of LXRα 
activation has been documented in viral infections, i flammatory diseases, and the 
above-mentioned cardiometabolic disorders in basic cience studies [58-60]. 
Activation of LXRα by agonists downregulates the expression of inflamm tory genes 
through a trans-repression process [61,62]. Our current finding further confirmed the 
anti-inflammatory effect of LXRα as evidenced by the downregulation of LXRα and 
increased inflammatory response within atherosclerotic lesions in ADMA-treated 
apoE-/- mice compared to those in vehicle-treated apoE-/- mice. Regarding the 
interaction between LXRα and NOX-ROS signaling, most studies on LXRα 
demonstrated that activation of LXRα by agonists protects cells from ROS-mediated 
injury or inflammation [63,64]; however, we do not have evidence to support the 
effect of ROS on LXRα activation and the underlying mechanism. Thus, additional 
studies to delineate the effect of NOX-ROS signaling on LXRα-mediated 
cardiovascular benefits are warranted. 
However, our study contains several limitations. Our in vitro experiments 
employed the mouse macrophage J774.A1 cell line and human THP-1 cell line. It is 
important to confirm the implication of ADMA in cholesterol metabolism of 
macrophages by using primary human monocyte-derived macrophages. We did not 
investigate the effects of ADMA on lipid metabolism in primary human 
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monocyte-derived macrophages in this study for the reason that our labs are not 
certified to perform experiments using human samples. Integrated RCT from 
macrophages to liver and feces plays a crucial rolein regulating the cholesterol 
homeostasis of whole body under pathophysiological ondition [53-55,65,66]. 
Nevertheless, we did not determine the role of ADMA in macrophage-specific RCT 
in vivo. From the point in search of molecular mechanisms underlying the 
pathogenesis of lipid deregulation in vivo, the more informative mouse models used 
in the studies by Zhang et al. or Jessup et al. are required for evaluating the specific 
role of macrophages in ADMA-mediated deregulation in RCT under physiological 
condition [65,66]. To this end, further investigations describing the implications of 
macrophage-specific RCT in ADMA-mediated deregulation of cholesterol 
homeostasis in vivo are warranted. 
In conclusion, ADMA likely has a pro-atherogenic effect based on experimental 
evidence showing that ADMA inhibits the oxLDL-induced activation of the LXRα 
pathway and downregulates the expression of ABCA1 and ABCG1, resulting in the 
impairment of cholesterol efflux and increased lipid accumulation in macrophage 
foam cells and consequently accelerating the progression of atherosclerosis. The 
molecular mechanisms we revealed indicate a broader biological impact of ADMA on 
vascular biology and suggest novel a pharmacological target for treating 
atherosclerosis and related cardiovascular diseases.  
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Figure Legends 
 
Fig. 1. Effect of oxLDL on the macrophage ADMA/DDAH-2 system. (A) Aortas 
were collected from 5-month-old apoE-/- mice. Immunostaining was performed with 
normal rabbit IgG, anti-DDAH-1, anti-DDAH-2, or anti-F4/80 antibody, a 
macrophage marker. Cell nuclei were stained with hematoxylin. Bar = 50 µm. Murine 
J774.A1 macrophages or human THP-1-derived macrophages were treated with 
indicated concentrations of oxLDL for 24 h. (B and D) Western blot analysis of 
DDAH-1, DDAH-2, and α-tubulin. (C and E) Intracellular ADMA was measured by 
ELISA assays. Data are the mean ± SEM from five independent experiments. *P < 
0.05 vs. the vehicle group. 
Fig. 2. Effect of ADMA on the oxLDL-induced lipid accumulation. Murine 
J774.A1 macrophages or human THP-1-derived macrophages were treated with 
indicated concentrations of ADMA in the presence of oxLDL (50 µg/ml) for 24 h. (A) 
Intracellular cholesterol and triglycerides were extracted and measured using an 
enzymatic method. Data are the mean ± SEM from five independent experiments. (B) 
Representative microscopy images of oil red O staining. (C and E) Cells were treated 
with indicated concentrations of ADMA with or without Dil-oxLDL (2 µg/ml). Fold 
change in lipid accumulation in macrophages by fluorescent assay. (D and F) 
Representative fluorescent microscopy images of lipid accumulation. Scale bar = 10 
µm. *P < 0.05 vs. the vehicle group; #P < 0.05 vs. the oxLDL alone group. 
Fig. 3. Effect of ADMA on oxLDL internalization and SR expression. (A and D) 
Murine J774A.1 macrophages or human THP-1-derived macrophages were treated 
with vehicle or ADMA (0.5 µM) for 24 h then incubated with 2 µg/ml Dil-oxLDL at 4 
°C for 4 h. Fold change in lipid binding on surface of macrophages by fluorescent 
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assay. (B, C, E and F) Western blot analysis of SR-A, CD36, and α-tubulin. Data are 
the mean ± SEM from five independent experiments. *P < 0.05 vs. the vehicle group. 
Fig. 4. The implication of ADMA in cholesterol efflux and expression of 
cholesterol transporters. (A, B, D and E) Murine J774A.1 macrophages or human 
THP-1-derived macrophages were treated with indicated treatments; apoAI- or 
HDL-dependent cholesterol efflux was determined by fluorescent assay. (C and F) 
Macrophages were incubated with indicated treatments for 24 h. Western blot analysis 
of ABCA1, ABCG1, SR-BI, and α-tubulin. Data are the mean ± SEM from five 
independent experiments. *P < 0.05 vs. the vehicle group; #P < 0.05 vs. the oxLDL 
alone group. 
Fig. 5. Effect of ADMA on LXRα activation. (A) J774A.1 macrophages were 
incubated with the indicated treatments for 6 h. Real-time PCR analysis of mRNA 
levels of ABCA1, ABCG1, or GAPDH. (B) Western blot analysis of nuclear LXRα 
and Histone H1. (C) J774A.1 macrophages were transfected with 
pM-GAL-hLXRα with a GAL4-SEAP reporter for 24 h and then incubated with 
indicated reagents for another 24 h. The SEAP activity n the culture media was 
determined. Data are the mean ± SEM from five independent experiments. *P < 0.05 
vs. the vehicle group; #P < 0.05 vs. the oxLDL alone group.  
Fig. 6. Effect of DDAH-2 overexpression on the ADMA-mediated deregulation of 
cholesterol metabolism. (A) J774.A1 cells were infected with adenovirus (Ad) 
Ad-DDAH-2 (12.5-50 MOI) for 24 h. Western blot analysis of DDAH-2 and 
α-tubulin. (B and C) J774.A1 cells were infected with Ad-vector (Ad-null) or 
Ad-DDAH-2 (50 MOI) for 24 h, and then treated with ndicated treatments for 12 h; 
apoAI- or HDL-dependent cholesterol efflux was determined by fluorescent assay. (D) 
Fold change in lipid accumulation in macrophages by fluorescent assay after 
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Dil-oxLDL treatment for 24 h. (E) Representative fluorescent microscopy images of 
lipid accumulation. Scale bar = 20 µm. Data are the mean ± SEM from five 
independent experiments. *P < 0.05 vs. the vehicle group; #P < 0.05 vs. the oxLDL 
alone group; &P < 0.05 vs. the ADMA+oxLDL group. 
Fig. 7. Effect of ADMA on the activation of the NOX-ROS pathway. J77A1.A1 
macrophages were treated with ADMA (0.5 µg/ml) for the indicated times. (A) 
NADP+/NADPH assay, the intensity of (B) red fluorescent DHE, and (C) green 
fluorescent DCF, were analyzed. (D and E) Representative fluorescent microscopy 
images of ROS. Scale bar = 20 µm. Data are the mean ± SEM from five independent 
experiments. * P < 0.05 vs vehicle. 
Fig. 8. Effects of inhibition of NOX-ROS signaling on ADMA-induced ROS 
production and deregulation of cholesterol efflux. (A and B) J774.A1 cells were 
pretreated with or without an NOX inhibitor (apocynin; APO, 50 µM) or a ROS 
scavenger (N-acetylcysteine; NAC, 10 mM) for 2 h and then ADMA (0.5 µg/ml) for 
15 min. Intracellular levels of ROS were assessed. (C and D) J774.A1 macrophages 
were pretreated with or without APO or NAC for 2 h and then indicated treatments. 
ApoAI- or HDL-dependent cholesterol efflux was evaluated. (E) Fold change in lipid 
accumulation in macrophages by fluorescent assay (F) Representative fluorescent 
microscopy images of lipid accumulation. J774.A1 cells were transfected with or 
without NOX2 siRNA for 24 h, followed by indicated treatments. (G and H) 
Representative fluorescent images of ROS; (I) Intracellular lipid accumulation and (J) 
Representative fluorescent images of lipid accumulation. Scale bar = 20 µm. *P < 0.05 
vs. the vehicle group; #P < 0.05 vs. the oxLDL alone group; &P <0.05 vs. the ADMA+ 
oxLDL group. 
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Fig. 9. Effects of chronic treatment with ADMA on RCT and atherosclerosis in 
apoE-/- mice. Male apoE-/- mice received a daily administration of ADMA (5 mg/k , 
n=10) or saline (vehicle control, n=10) for 4 weeks. (A) Quantitation of 
atherosclerotic lesions in the aortic roots of vehicle-treated or ADMA-treated apoE-/- 
mice. (B) Serum levels of cholesterol, non-high-density lipoprotein cholesterol 
(non-HDL-c), HDL cholesterol (HDL-c) and triglycerides. (C) Western blotting 
analysis of aortic levels of LXRα, ABCA1, ABCG1, SR-BI, SR-A, CD36, and 
α-tubulin. (D) The reverse cholesterol efflux efficacy of serum. (E) Serum levels of 
tumor necrosis factor α (TNF-α), interleukin-1β (IL-1β), IL-6, monocyte chemotactic 
protein 1 (MCP-1), and macrophage inflammatory protein 2 (MIP-2). Data for each 
group are the mean ± SEM from 10 animals. *, P < 0.05 vs. vehicle-treated mice. 
Fig. 10. Schematic illustration of the proposed mechanism underlying the 
ADMA-mediated deregulation of cholesterol metabolism in macrophages. As 
shown, challenge with ADMA elicits the activation of the NOX-ROS pathway, which 
in turn reduces LXRα activity and downregulates the expression of ABCA1 and 
ABCG1, leading to the impairment of cholesterol efflux and ultimately increasing 
lipid accumulation in macrophages. 
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1. ADMA exacerbates oxLDL-induced lipid accumulation in macrophage foam cells. 
 
2. ADMA impairs cholesterol efflux by decreasing the expression and activity of 
LXRα. 
 
3. DDAH-2 overexpression prevents the detrimental effects of ADMA on cholesterol 
efflux. 
 
4. ADMA activates the NOX/ROS signaling pathway. 
 
5. ADMA exacerbates hyperlipidemia, inflammation and atherosclerosis in apoE-/- 
mice. 
 
